Aller au contenu principal
Profil bibliographique

Steve D. Paget

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
184Citations signalées
2Affiliations récentes

Les institutions déclarées

Les domaines associés

Tuberculosis Research and EpidemiologyComputational Drug Discovery MethodsCancer therapeutics and mechanismsAntimicrobial Resistance in StaphylococcusCancer-related Molecular Pathways

Les publications récentes

Accès ouvert 2019 article OpenAlex

Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor of Mycobacterium tuberculosis

Xin Wang, Alexander L. Perryman, Shaogang Li, Steve D. Paget et autres

Tuberculosis, caused by Mycobacterium tuberculosis ( M. tuberculosis ), kills 1.6 million people annually. To bridge the gap between structure- and cell-based drug discovery strategies, we are pioneering a computer-aided discovery paradigm that merges structure-based virtual screening with ligand-based, machine learning methods …

us (code pays fourni par la source)

29 citations ACS Infectious Diseases
2014 conference-abstract OpenAlex

Abstract 2528: Optimization of small molecules targeting BMI1 protein expression. Part 2. Improved potency, oral bioavailability, and in vivo efficacy of amino-pyrazines and amino-pyridines

Ramil Baiazitov, Nadiya Sydorenko, Hongyu Ren, Wu Du et autres

Abstract Earlier, in our efforts to identify molecules that selectively deplete tumor stem cells, we discovered and elaborated on a series of amino-thiazoles. These first-in-class small molecule inhibitors reduce the activity and levels of BMI1 protein in vitro and in vivo (see …

us (code pays fourni par la source)

0 citations Cancer Research
Accès ouvert 2006 article OpenAlex

In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457

Barbara D. Foleno, Darren Abbanat, Raul M. Goldschmidt, Robert K. Flamm et autres

RWJ-416457, an investigational pyrrolopyrazolyl-substituted oxazolidinone, inhibited the growth of linezolid-susceptible staphylococci, enterococci, and streptococci at concentrations of < or =4 microg/ml, generally exhibiting two- to fourfold-greater potency than that of linezolid. Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid.

us (code pays fourni par la source)

21 citations Antimicrobial Agents and Chemotherapy

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.